Differential Modulation of Human M1 and M2 Macrophage Activity by ICOS-Mediated ICOSL Triggering.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
02 Feb 2023
Historique:
received: 09 12 2022
revised: 26 01 2023
accepted: 31 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 15 2 2023
Statut: epublish

Résumé

Activated T cells express the inducible T-cell co-stimulator (ICOS) that, upon binding to its ubiquitously expressed ligand (ICOSL), regulates the immune response and tissue repair. We sought to determine the effect of ICOS:ICOSL interaction on human M1 and M2 macrophages. M1 and M2 macrophages were polarized from monocyte-derived macrophages, and the effect of a soluble recombinant form of ICOS (ICOS-CH3) was assessed on cytokine production and cell migration. We show that ICOS-CH3 treatment increased the secretion of CCL3 and CCL4 in resting M1 and M2 cells. In LPS-treated M1 cells, ICOS-CH3 inhibited the secretion of TNF-α, IL-6, IL-10 and CCL4, while it increased that of IL-23. In contrast, M2 cells treated with LPS + IL4 displayed enhanced secretion of IL-6, IL-10, CCL3 and CCL4. In CCL7- or osteopontin-treated M1 cells, ICOS-CH3 boosted the migration rate of M1 cells while it decreased that of M2 cells. Finally, β-Pix expression was upregulated in M1 cells and downregulated in M2 cells by treatment with ICOS-CH3. These findings suggest that ICOSL activation modulates the activity of human M1 and M2 cells, thereby eliciting an overall anti-inflammatory effect consistent with its role in promoting tissue repair.

Identifiants

pubmed: 36769276
pii: ijms24032953
doi: 10.3390/ijms24032953
pmc: PMC9917690
pii:
doi:

Substances chimiques

Inducible T-Cell Co-Stimulator Protein 0
Interleukin-10 130068-27-8
Interleukin-6 0
Lipopolysaccharides 0
ICOS protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Italian Association for Cancer Research
ID : IG 20714
Organisme : University of Turin
ID : ex 60%, DIAC_RILO_21
Organisme : European Union
ID : Horizon 2020 research and innovation program under grant agreement No 814410 (GIOTTO)

Références

J Immunol. 2013 Feb 1;190(3):1125-34
pubmed: 23275603
Cancer Immunol Immunother. 2001 Mar;50(1):51-9
pubmed: 11315510
Immunity. 2014 May 15;40(5):734-46
pubmed: 24837102
PLoS One. 2013 Oct 21;8(10):e78045
pubmed: 24205083
Cell Immunol. 2013 Jan;281(1):51-61
pubmed: 23454681
Int Immunol. 2002 Jun;14(6):555-66
pubmed: 12039907
Br J Haematol. 2022 Mar;196(6):1369-1380
pubmed: 34954822
Front Immunol. 2018 Nov 15;9:2650
pubmed: 30524429
Nat Rev Immunol. 2002 Feb;2(2):116-26
pubmed: 11910893
J Cell Physiol. 2018 Sep;233(9):6425-6440
pubmed: 29319160
Cytokine. 2013 Oct;64(1):322-30
pubmed: 23778031
Int J Mol Sci. 2022 Jul 01;23(13):
pubmed: 35806368
J Immunol. 2016 Sep 15;197(6):2400-8
pubmed: 27534549
J Immunol. 2014 May 15;192(10):4921-31
pubmed: 24729612
Nat Immunol. 2009 Feb;10(2):167-75
pubmed: 19098919
Commun Biol. 2020 Oct 26;3(1):615
pubmed: 33106594
Am J Pathol. 2011 Nov;179(5):2360-9
pubmed: 21925472
Immunology. 2011 Aug;133(4):397-408
pubmed: 21631495
Oncotarget. 2017 Dec 14;9(6):7204-7218
pubmed: 29467962
Eur J Pharmacol. 2022 Jul 5;926:175018
pubmed: 35537492
J Immunol Res. 2016;2016:9345495
pubmed: 27478856
Clin Immunol. 2005 Apr;115(1):19-25
pubmed: 15870016
J Neuroinflammation. 2014 Feb 01;11:23
pubmed: 24485070
J Immunol. 2016 Nov 15;197(10):3905-3916
pubmed: 27798154
Cell Mol Life Sci. 2009 Sep;66(18):3067-80
pubmed: 19603141
J Control Release. 2020 Apr 10;320:112-124
pubmed: 31962094
Immunol Rev. 2009 May;229(1):101-13
pubmed: 19426217
Front Immunol. 2021 Dec 03;12:786680
pubmed: 34925367
Front Immunol. 2022 Sep 02;13:992614
pubmed: 36119089
PLoS One. 2014 Apr 24;9(4):e96053
pubmed: 24763697
Eur J Immunol. 2006 Oct;36(10):2601-12
pubmed: 17013990
J Immunol. 2010 Oct 1;185(7):3970-9
pubmed: 20817864

Auteurs

Casimiro Luca Gigliotti (CL)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
NOVAICOS s.r.l.s, Via Amico Canobio 4/6, 28100 Novara, Italy.

Chiara Dianzani (C)

Department of Scienza e Tecnologia del Farmaco, University of Turin, 10125 Turin, Italy.

Ian Stoppa (I)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.

Chiara Monge (C)

Department of Scienza e Tecnologia del Farmaco, University of Turin, 10125 Turin, Italy.

Salvatore Sutti (S)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.

Daniele Sblattero (D)

Department of Life Sciences, University of Trieste, 34127 Trieste, Italy.

Chiara Puricelli (C)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
Clinical Biochemistry Laboratory, Maggiore della Carità University Hospital, 28100 Novara, Italy.

Roberta Rolla (R)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
Clinical Biochemistry Laboratory, Maggiore della Carità University Hospital, 28100 Novara, Italy.

Umberto Dianzani (U)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
Clinical Biochemistry Laboratory, Maggiore della Carità University Hospital, 28100 Novara, Italy.

Elena Boggio (E)

Department of Health Sciences, Università del Piemonte Orientale, 28100 Novara, Italy.
NOVAICOS s.r.l.s, Via Amico Canobio 4/6, 28100 Novara, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH